BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S, Rovelli F. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 1999;80:407-11. [PMID: 10408846 DOI: 10.1038/sj.bjc.6690371] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ, Yan X. Melatonin as a potential anticarcinogen for non-small-cell lung cancer. Oncotarget 2016;7:46768-84. [PMID: 27102150 DOI: 10.18632/oncotarget.8776] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 20.3] [Reference Citation Analysis]
2 Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion. Lung Cancer 2001;31:303-10. [DOI: 10.1016/s0169-5002(00)00192-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
3 Melichar B, Spisarová M, Bartoušková M, Krčmová LK, Javorská L, Študentová H. Neopterin as a biomarker of immune response in cancer patients. Ann Transl Med 2017;5:280. [PMID: 28758106 DOI: 10.21037/atm.2017.06.29] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
4 Porta C, Pedrazzoli P, Paglino C. Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. Immunotherapy 2011;3:487-90. [PMID: 21463189 DOI: 10.2217/imt.11.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Lissoni P. Therapy implications of the role of interleukin-2 in cancer. Expert Review of Clinical Immunology 2017;13:491-8. [DOI: 10.1080/1744666x.2017.1245146] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
6 Lissoni P, Bonfanti A, Bordin V, Barni S, Vigore L, Ferrante R, Rovelli F, Fumagalli L. Changes in Circulating Immature and Mature Dendritic Cells During IL-2 Cancer Immunotherapy and Their Relation with Lymphocyte Increase and Clinical Response. Hematology 2016;5:117-25. [DOI: 10.1080/10245332.2000.11746494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Tunuguntla HS, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 2008;179:2096-102. [PMID: 18423738 DOI: 10.1016/j.juro.2008.01.083] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
8 van Spronsen DJ, de Weijer KJM, Mulders PFA, De Mulder PHM. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti-Cancer Drugs 2005;16:709-17. [DOI: 10.1097/01.cad.0000167901.58877.a3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
9 Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010;103:1154-62. [PMID: 20808314 DOI: 10.1038/sj.bjc.6605872] [Cited by in Crossref: 130] [Cited by in F6Publishing: 119] [Article Influence: 11.8] [Reference Citation Analysis]
10 Berdowska A, Zwirska-korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001;26:319-29. [DOI: 10.1046/j.1365-2710.2001.00358.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 128] [Article Influence: 7.5] [Reference Citation Analysis]
11 Kashyap MK, Kumar A, Emelianenko N, Kashyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK, Bhargave AK, Upadhyaya SK. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 2008;10:258-94. [DOI: 10.1080/13547500500218534] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
12 Yildirim Y, Gunel N, Coskun U, Pasaoglu H, Aslan S, Cetin A. Serum neopterin levels in patients with breast cancer. Med Oncol 2008;25:403-7. [DOI: 10.1007/s12032-008-9054-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
13 Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV, Edwards RP. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010;59:293-301. [PMID: 19690855 DOI: 10.1007/s00262-009-0750-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
14 Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astara G, Macciò A, Serpe R. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. J Exp Ther Oncol 2003;3:205-19. [PMID: 14567291 DOI: 10.1046/j.1359-4117.2003.01096.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
15 Jeong IG, Han KS, Joung JY, Choi WS, Hwang SS, Yang SO, Seo HK, Chung J, Lee KH. Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival. J Korean Med Sci 2007;22 Suppl:S122-8. [PMID: 17923738 DOI: 10.3346/jkms.2007.22.S.S122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014;89:129-139. [PMID: 24029605 DOI: 10.1016/j.critrevonc.2013.08.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 10.6] [Reference Citation Analysis]
17 Melichar B, Solichová D, Svobodová I, Melicharová K. Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin. Luminescence 2005;20:311-4. [DOI: 10.1002/bio.852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
18 Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L, Vaghi M, Ardizzoia A, Gardani G. Efficacy of Cancer Chemotherapy in Relation to the Pretreatment Number of Lymphocytes in Patients with Metastatic Solid Tumors. Int J Biol Markers 2004;19:135-40. [DOI: 10.1177/172460080401900208] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 21.0] [Reference Citation Analysis]
19 Lissoni P, Rovelli F. Principles of psychoneuroendocrinoimmunotherapy of cancer. Immunotherapy 2012;4:77-86. [PMID: 22150002 DOI: 10.2217/imt.11.158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
20 Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003;26:394-402. [PMID: 12973028 DOI: 10.1097/00002371-200309000-00002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.2] [Reference Citation Analysis]
21 Lissoni P, Rovelli F, Vigorè L, Messina G, Lissoni A, Porro G, Di Fede G. How to Monitor the Neuroimmune Biological Response in Patients Affected by Immune Alteration-Related Systemic Diseases. Methods Mol Biol 2018;1781:171-91. [PMID: 29705848 DOI: 10.1007/978-1-4939-7828-1_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Lissoni P, Rovelli F, Malugani F, Brivio F, Fumagalli L, Gardani G. Changes in Circulating VEGF Levels in Relation to Clinical Response during Chemotherapy for Metastatic Cancer. Int J Biol Markers 2003;18:152-5. [DOI: 10.1177/172460080301800209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
23 Tourani J, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero J, Mayeur D, Rixe O, Sun X, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J. Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design—The Subcutaneous Administration Propeukin Program Cooperative Group. JCO 2003;21:3987-94. [DOI: 10.1200/jco.2003.02.073] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
24 Beuselinck B, Vano Y, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib: Prognostic impact of CRP on metastatic RCC outcomes. BJU Int 2014;114:81-9. [DOI: 10.1111/bju.12494] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
25 Guida M, Ravaioli A, Sileni VC, Romanini A, Labianca R, Freschi A, Brugnara S, Casamassima A, Lorusso V, Nanni O, Ridolfi R. Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. J Transl Med 2003;1:13. [PMID: 14690541 DOI: 10.1186/1479-5876-1-13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
26 Shah JB, Margulis V. In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:837-42. [PMID: 20553209 DOI: 10.1586/era.10.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
27 Wang Y, Zhang Y. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis. Clin Transl Oncol 2020;22:835-43. [DOI: 10.1007/s12094-019-02192-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]